Literature DB >> 16209070

Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.

John W Eklund1, Timothy M Kuzel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16209070     DOI： 10.1007/0-387-24361-5_11

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  4 in total

1.  Cancer vaccines.

Authors:  Margaret A Liu
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

2.  Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production.

Authors:  James T Snyder; Jijia Shen; Hooman Azmi; Jeannie Hou; Daniel H Fowler; Jack A Ragheb
Journal:  Blood       Date:  2007-03-07       Impact factor: 22.113

3.  Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells.

Authors:  Yunshan Yang; Fangming Xiu; Zhijian Cai; Jianli Wang; Qingqing Wang; Yangxin Fu; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-12       Impact factor: 4.322

4.  Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique and of probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors.

Authors:  Klabusay Martin; Kohutova Viera; Coupek Petr; Nenickova Marie; Tesarova Eva
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.